2023 - Research.com Medicine in Canada Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Canada Leader Award
2000 - Canada Gairdner International Award
1999 - Fellow of the Royal Society of Canada Academy of Science
Member of the Association of American Physicians
Surgery, Anticoagulant, Heparin, Thrombosis and Anesthesia are his primary areas of study. The concepts of his Surgery study are interwoven with issues in Placebo and Warfarin. His study in Anticoagulant is interdisciplinary in nature, drawing from both Coagulopathy, Chemotherapy, Phenylbutazone, Confidence interval and Obstetrics.
His research in Heparin intersects with topics in Discovery and development of direct thrombin inhibitors, Pharmacology and Partial thromboplastin time. His Thrombosis research integrates issues from Radiology, Vascular disease and Vein. His biological study spans a wide range of topics, including Regimen, Clopidogrel, Aspirin and Warfarin Sodium.
Jack Hirsh mostly deals with Heparin, Surgery, Internal medicine, Thrombosis and Anesthesia. His research in Heparin intersects with topics in Anticoagulant, Pharmacology and Partial thromboplastin time. His Surgery study frequently intersects with other fields, such as Warfarin.
Jack Hirsh has researched Internal medicine in several fields, including Gastroenterology, Endocrinology and Cardiology. His work investigates the relationship between Thrombosis and topics such as Radiology that intersect with problems in Plethysmograph. His Anesthesia research includes themes of Placebo and Blood coagulation test.
Jack Hirsh mainly focuses on Anesthesia, Internal medicine, Surgery, Randomized controlled trial and Intensive care medicine. His Anesthesia research incorporates elements of Dabigatran, Warfarin, Heparin, Anticoagulant and Clopidogrel. Internal medicine is frequently linked to Cardiology in his study.
Thrombosis and Low molecular weight heparin are the primary areas of interest in his Surgery study. His Thrombosis study integrates concerns from other disciplines, such as Pulmonary embolism and Hip surgery. His Intensive care medicine research incorporates themes from Venous thromboembolism, Clinical trial and Antithrombotic.
His primary scientific interests are in Anesthesia, Antithrombotic, Intensive care medicine, Randomized controlled trial and Internal medicine. Jack Hirsh interconnects Clopidogrel and Warfarin in the investigation of issues within Anesthesia. His Antithrombotic research is multidisciplinary, relying on both Guideline, Physical therapy, Clinical trial and Evidence-based medicine.
His Randomized controlled trial study results in a more complete grasp of Surgery. Thrombosis and Multicenter study are the core of his Surgery study. His research on Internal medicine often connects related areas such as Cardiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Jack Hirsh;Valentin Fuster;Jack Ansell;Jonathan L. Halperin.
Circulation (2003)
Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine
Gordon Guyatt;John Cairns;David Churchill;Deborah Cook.
JAMA (1992)
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
Theodore E. Warkentin;Mark N. Levine;Jack Hirsh;Peter Horsewood.
The New England Journal of Medicine (1995)
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Jack Ansell;Jack Hirsh;Elaine Hylek;Alan Jacobson.
Chest (2008)
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Jack Hirsh;James E. Dalen;David R. Anderson;Leon Poller.
Chest (2001)
The Pharmacology and Management of the Vitamin K Antagonists : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Jack Ansell;Jack Hirsh;Leon Poller;Henry Bussey.
Chest (2004)
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
Philip S. Wells;David R. Anderson;Marc Rodger;Jeffrey S. Ginsberg.
Thrombosis and Haemostasis (2000)
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Jack Hirsh;Theodore E. Warkentin;Stephen G. Shaughnessy;Sonia S. Anand.
Chest (2001)
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Mark Levine;Michael Gent;Jack Hirsh;Jacques Leclerc.
The New England Journal of Medicine (1996)
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events
John W. Eikelboom;Jack Hirsh;Jeffrey I. Weitz;Marilyn Johnston.
Circulation (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
McMaster University
Population Health Research Institute
McMaster University
McMaster University
McMaster University
McMaster University
McMaster University
McMaster University
McMaster University
University of Arizona
University of Illinois at Urbana-Champaign
French Institute for Research in Computer Science and Automation - INRIA
University of Basel
Leipzig University
Institut Gustave Roussy
University of Washington
University of Sydney
University of British Columbia
Imperial College London
Wageningen University & Research
Emory University
University of Southern California
Oslo University Hospital
Copenhagen University Hospital
University of KwaZulu-Natal
Florida State University